EsoCap AG
Effective topical treatment of the esophagus is difficult due to the ultra-short transit time of only seconds from mouth to stomach. EsoCap has developed a versatile drug delivery platform that enables efficient, localized administration of small molecules, antibodies, and RNA-based therapies. The technology supports improved treatment of EoE, reflux disease, esophageal cancer, and other gastrointestinal disorders by enhancing mucosal contact and therapeutic precision.
Category
Clinical stage development company
Title of the presentation
Transforming Esophageal Drug Delivery: A Platform Approach with EsoCap
Speaker information
| Name | Position | Institution |
|---|---|---|
| Isabelle Racamier | CEO | EsoCap AG |
